PORTFOLIO NEWS Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 8, 2023 Read More » ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates November 6, 2023 Read More » RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC November 3, 2023 Read More » A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting November 2, 2023 Read More » NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights November 2, 2023 Read More » Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial November 1, 2023 Read More » Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy October 26, 2023 Read More » Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference October 23, 2023 Read More » ORIC-114’s Initial Phase 1 Dose Escalation Data in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile October 21, 2023 Read More » Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy October 19, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 8, 2023 Read More »
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates November 6, 2023 Read More »
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC November 3, 2023 Read More »
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting November 2, 2023 Read More »
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights November 2, 2023 Read More »
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial November 1, 2023 Read More »
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy October 26, 2023 Read More »
Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference October 23, 2023 Read More »
ORIC-114’s Initial Phase 1 Dose Escalation Data in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile October 21, 2023 Read More »
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy October 19, 2023 Read More »
